PTSD
Posttraumatic stress disorder (PTSD) is a significant mental health challenge affecting over 354 million individuals globally. Psychedelics, particularly MDMA and psilocybin, are emerging as promising therapeutic options, offering new avenues for treatment through innovative psychotherapeutic interventions.
What is PTSD?
Posttraumatic stress disorder (PTSD) is a psychiatric condition that arises following a traumatic event, including natural disasters, violence, war, and sexual assault. The disorder is characterised by a range of symptoms grouped into four categories: intrusive memories, avoidance behaviours, negative changes in cognition and mood, and alterations in emotional and physical responses.
Common symptoms include distressing recollections of the traumatic experience, avoidance of reminders, negative self-perception, heightened startle response, and emotional numbing. To be diagnosed with PTSD, a person must exhibit symptoms persisting for more than one month, which disrupt daily functioning.
Current Treatments
Standard treatment for PTSD often combines psychotherapy (including cognitive processing therapy and prolonged exposure therapy) with pharmacotherapy, predominantly SSRIs such as paroxetine and sertraline. Anxiolytics may be used short-term, but they carry an abuse risk.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for PTSD.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| MDMA Strong evidence from multiple Phase II and Phase III trials shows substantial efficacy in treating PTSD. | Large | High | Consistent |
| Ketamine Initial positive trials indicate efficacy but larger studies yield mixed results. | Medium | Moderate | Inconsistent |
| Psilocybin Emerging research suggests potential benefits, but more rigorous studies are needed. | Small | Low | Inconsistent |
| Mescaline Limited surveys suggest anecdotal benefits without controlled trials. | Small | Very Low | Inconsistent |
MDMA and PTSD
MDMA is classified as an entactogen, which promotes feelings of emotional openness and empathy—critical for processing traumatic experiences. It functions primarily by increasing serotonin levels, thereby enhancing emotional fluidity during therapeutic sessions. This heightened state of receptiveness enables therapeutic breakthroughs as individuals confront and reframe their traumatic memories with the guidance of a trained therapist.
Ketamine and PTSD
Ketamine acts as an NMDA receptor antagonist, leading to an increase in glutamate levels which may stimulate synaptogenesis and enhance neural activity. This mechanism is theorised to alleviate depressive symptoms associated with PTSD, although the lack of structured therapy in studies complicates the understanding of its efficacy specifically for PTSD treatment.
Key Insights
- 1
MDMA-assisted therapy has demonstrated very large effects, with 56% of participants no longer meeting PTSD criteria in early trials.
- 2
The majority of participants in MDMA trials were war veterans, a demographic which shows higher PTSD prevalence compared to the general population.
- 3
Ketamine shows promise in reducing PTSD symptoms, but results are mixed, with some studies indicating limited dosage effects and transient benefits.
- 4
Mescaline remains under-researched in PTSD treatment, but user surveys suggest potential symptom improvement.
- 5
Psychedelics like MDMA may 'reopen' critical periods for emotional processing, facilitating therapeutic breakthroughs.
Industrial Landscape
Key players in this field include MAPS (Multidisciplinary Association for Psychedelic Studies), which has been pivotal in advancing MDMA therapy; Numinus, focusing on therapeutic psychedelic applications; and Seelos Therapeutics, working on ketamine formulation. Non-profits such as Healing Breakthrough and Remedy are also instrumental in research and clinical applications for PTSD.
Quick Indicators
\"Ongoing clinical evaluations are investigating PTSD as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with PTSD.